Mice Model Market - By Mice (Inbred, Outbred, Knockout, Hybrid), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application, By Use, By End-use & Forecast, 2023 – 2032

Mice Model Market Size

Mice Model Market size exceeded USD 9.5 billion in 2022 and will depict over 6% CAGR from 2023 to 2032, driven by rising demand for humanized mice models.

The genetic resemblance between mice and humans is positively influencing market growth and boosting the demand for mouse models in biomedical research. The positive inclination of researchers toward the study of human diseases using mouse models as humans share more than 95% of their protein-coding and over 28% of non-coding sequences with mice genome, is set to provide lucrative opportunities to the market.

Despite a positive outlook for the mice model market, ongoing developments of alternative methods for animal testing will negatively influence product adoption. Researchers are compelled to find strategies to save time and employ fewer animals in drug screening procedures since millions of experimental animals are utilized each year globally. Scientists have therefore devised other methods that would reduce the number of mice employed as research subjects. Nonetheless, promising developments in the field would aid in overcoming this issue.

Mice Model Market Analysis

In terms of mice, the inbred mice model market will reach over USD 4.5 billion by 2032. The growing adoption of inbred mice for studying the genetic bases of phenotypic variation and the rising use in cancer research for understanding the genetic basis of tumor development and cancer progression is bolstering segment development. For instance, inbred mice are commonly used to reproduce DIO models to reduce modeling time and attain stable metrics.
 

The mice model market revenue size from the CRISPR technology segment will reach more than USD 6 billion by the end of 2032. This is attributed to its cost-effectiveness, time efficiency, and convenience compared to traditional gene editing techniques such as transcription activators-like effective nucleases (TALENS). Moreover, growing awareness regarding the advantages of CRISPR technology is promoting product demand. A 2022 study highlighted that 54 of 85 isolates of enterococci species indicated a presence of CRISPR-Cas loci, accounting for more than 63% of total samples.

Regionally, North America accounted for over 80% of the mice model market revenue in 2022, attributed to the high prevalence of chronic diseases including diabetes and viral diseases. As per a recent report, by 2060, people under age 20 with type 2 diabetes would increase by approximately 675% in the U.S. Moreover, several research organizations in the region are also focusing on developing effective therapeutic drugs for the treatment of viral diseases, which is increasing the demand for mice models.

Mice Model Market Share

Some of the key players profiled in the mice model market report include

• Charles River Laboratories International Inc
• Taconic Biosciences, Inc.
• Janvier Labs
• genOway
• Hera Biolabs
• TransViragen Inc.
• The Jackson Laboratory
• Inotiv
• Allentown LLC
• Harbour Biomed
• PolyGene

These firms engage in promising acquisitions and mergers to propel their market position.

Mice Model Industry News

• In September 2022, genOway, a biotechnology firm, expanded its partnership with Sigma-Aldrich, a science and tech subsidiary of Merck. With this, both companies agreed to continue collaborative R&D programs and innovations in CRISPR/Cas9 rodent model market and boost the CRISPR patent portfolio.
   
• In October 2022, Taconic Biosciences, Inc., an animal model solutions provider, introduced the FcResolv NOG collection, a range of highly immunodeficient mice models missing residual murine Fc gamma receptors. The new portfolio is applicable in oncology, immune-oncology, and autoimmune diseases, to engraft multiple human cells and tissues.
   

The mice model market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market Size, By Mice

• Inbred
• Outbred
• Knockout
• Hybrid
• Other Mice

Market Size, By Technology

• CRISPR
• Microinjection
• Embryonic Stem Cell Injection
• Nuclear Transfer
• Other Technologies

Market Size, By Application

• Research & Development
  • Infectious Disease
  • Immunological Diseases
  • Cancer
  • Cardiovascular Diseases
  • Diabetes
  • Genetic Diseases
  • Neurological Diseases
  • Other Diseases
• Production and Quality Control
• Academics
• Other Applications

Market Size, By Use

• Human
• Veterinary

Market Size, By End-use

• Companies
  • Pharmaceutical
  • Biotechnology
  • Cosmetics
  • Other Companies
• Organisations
  • Government
  • Non-government
• Academic and Research Institutes
• Contract Research Organizations (CRO)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Netherlands
  • Czech Republic
  • Poland
  • Belgium
  • Finland
  • Hungary
  • Denmark
  • Ireland
  • Sweden
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Australia
  • South Korea
  • New Zealand
  • Taiwan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Rest of Middle East & Africa